| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
11 |
| Employees |
79 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-24 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Contrafect Corporation, founded in 2008, is a clinical-stage biotechnology company that uses genetic engineering technology to create innovative therapies for the treatment of infectious diseases. Its headquarters is located in Yonkers, New York, and is led by Roger Pomerantz, the CEO and President.
Contrafect's approach to fighting infectious diseases is based on targeting specific bacterial pathogens and then using their own natural defense mechanisms to destroy them. The company uses monoclonal antibodies (mAbs) as a therapeutic tool to fight against infections. These antibodies can target bacteria from inside the body and stop them from replicating, thereby helping the patientes immune system fight and eliminate the disease.
The company's lead product candidate, CF-301, is a recombinant protein that targets the bacterium Staphylococcus aureus (S. aureus) and is undergoing clinical trials. S. aureus is a major cause of hospital-acquired and community-acquired infections, including pneumonia and bloodstream infections. CF-301 is designed to be used in combination with standard-of-care antibiotics to enhance their efficacy and reduce the risk of antibiotic resistance.
Contrafect has also developed a proprietary antibody discovery platform, mAbSeqe, which uses rapid sequencing of antigen-specific B cells to discover mAbs with superior binding properties. It has several other research programs underway to discover and develop new treatments for other infectious diseases.
In addition to its research and development efforts, Contrafect has also made strategic partnerships with other companies in the pharmaceutical industry. For instance, it licensed CF-301 to UK-based pharmaceutical company, GSK, for commercialization in Europe for use in combination with other antibiotics.
Overall, Contrafect is a cutting-edge biotechnology company dedicated to developing innovative therapies to combat infectious diseases, particularly antibiotic-resistant bacteria. With a strong leadership team, a robust research pipeline, and a focus on partnership and collaboration, Contrafect is well poised to make an impact in the world of infectious disease treatment.
Company Address: 28 Wells Avenue Yonkers 10701 NY
Company Phone Number: 207-2300 Stock Exchange / Ticker: NASDAQ CFRX
|
%
2.23% 